Adaptive and maladaptive hypertrophic pathways: Points of convergence and divergence

Cardiovascular Research

Volumn 63, Issue 3, 2004, Pages 373-380

  Selvetella, Giulio ^a   Hirsch, Emilio ^b   Notte, Antonella ^a   Tarone, Guido ^b   Lembo, Giuseppe ^a,c  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Left ventricular hypertrophy; Pressure overload; Signaling; Transgenic mice

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ADAPTATION; DISEASE ASSOCIATION; DRUG EFFECT; EXERCISE; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; MECHANICAL STRESS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTATION, PHYSIOLOGICAL; ANIMALS; CALCINEURIN; CARDIOMYOPATHY, DILATED; HUMANS; MAP KINASE SIGNALING SYSTEM; MYOCARDIUM; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 3242774502     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.04.031     Document Type: Review

References (96)

1. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad and the ugly. Annu. Rev. Physiol. 65:2003;45-79
2. Russel B., Motlagh D., Ashley W.W. Form follows function: How muscle shape is regulated by work. J. Appl. Physiol. 88:2000;1127-1132
3. Sadoshima J., Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 59:1997;551-571
4. Urbanek K., Quaini F., Tasca G., Torella D., Castaldo C., Nadal-Ginard B., et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 100(18):2003 (Sep 2);10440-10445
5. Lips D.J., De Windt L.J., van Kraaij J.W., Doevandans P.A. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur. Heart J. 24:2003;883-896
6. James M.A., Saadeh A.M., Jones J.V. Wall stress and hypertension. J. Cardiovasc. Risk. 7:2000;187-190
7. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322:1990;1561-1566
8. Casale P.N., Devereux R.B., Milner M., Zullo G., Harshfield G.A., Pickering T.G., et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann. Intern. Med. 105:1986;173-178
9. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114:1991;345-352
10. Vakili B.A., Okin P.M., Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am. Heart J. 141:2001;334-341
11. Bolognese L., Dellavesa P., Rossi L., Sarasso G., Bongo A.S., Scianaro M.C. Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am. J. Cardiol. 73:1994;1-5
12. Matthew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., et al. Heart Outcomes Prevention Evaluation (HOPE)Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 104:2001;1615-1621
13. Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Zampi I., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 97:1998;48-54
14. Molkentin J.D., Dorn G.W. II Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63:2001;391-426
15. Morisco C., Sadoshima J., Trimarco B., Arora R., Vatner D.E., Vatner S.F. Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. Am. J. Physiol. Heart Circ. Physiol. 284(4):2003 Apr
16. Olson E.N., Williams R.S. Calcineurin signalling and muscle remodelling. Cell. 101:2000;689-692
17. Zhang W. Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy. Cardiovasc. Res. 53:2002;294-303
18. Crabtree G.R. Generic signals and specific outcomes: signalling through calcium, calcineurin, and NF-AT. Cell. 1999;611-614
19. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent trascriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228
20. Lim H.W., Molkentin J.D. Reply to revisiting calcineurin and human heart failure. Nat. Med. 6:2000;3
21. Rothermel B.A., McKinsey T.A., Vega R.B., Nicol R.L., Mammen P., Yang J., et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U.S.A. 98(6):2001;3328-3333
22. Hill J.A., Rothermel B., Yoo K.D., Nicol R.L., Mammen P., Yang J., et al. Targeted inhibition of calcineurin in pressure overload cardiac hypertrophy. Preservation of systolic function. J. Biol. Chem. 277:2002;10251-10255
23. Sakata Y., Masuyama T., Yamamoto K., Nishikawa N., Yamamoto H., Kondo H., et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation. 102(18):2000;2269-2275
24. Meguro T., Hong C., Asai K., Takagi G., McKinsey T.A., Olson E.N., et al. Cyclosporine attenuates pressure overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84:1999;735-740
25. Oie E., Bjornerheim R., Clausen O.P., Attramadal H. Cyclosporine A inhibits cardiuac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am. J. Physiol. Heart Circ. Physiol. 278(6):2000;H2115-H2123
26. Kemi O.J., Loennechen J.P., Wisloff U., Ellingsen O. Intensity-controlled treadmill running in mice: cardiac and skeletal muscle hypertrophy. J. Appl. Physiol. 93(4):2002;1301-1309
27. Eto Y., Yonekura K., Sonoda M., Arai N., Sata M., Sugiura S., et al. Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circ. 101:2000;2134-2137
28. Wilkins B.J., Dai Y.S., Bueno O., Parsons S.A., Xu J., Plank D.M., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94(1):2004;110-118
29. Sadoshima J.-I., Xu Y., Slayer H.S., Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 75:1993;977-984
30. Shubeita H.E., McDonough P.M., Harris A.N., Knowlton K.U., Glembotski C.C., Brown J.H., et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J. Biol. Chem. 265:1990;20555-20562
31. Maruyama Y., Nishida M., Sugimoto Y., Tanabe S., Turner J.H., Kozasa T., et al. Galfa (12/13) mediates alpha (1)-adrenergic receptor-induced cardiac hypertrophy. Circ. Res. 91(10):2002;961-969
32. Paradis P., Dali-Youcef N., Paradis F.W., Thibault G., Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocites induces cardiac hypertrophy and remodelling. Proc. Natl. Acad. Sci. U.S.A. 97:2000;931-936
33. Adams J.W., Sakata Y., Davis M.G., Sah V.P., Wang Y., Liggett S.B., et al. Enhanced Gαq signalling: a common pathway mediates cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U.S.A. 95:1998;10140-10145
34. D'Angelo D.D., Sakata Y., Lorenz J.N., Boivin G.P., Walsh R.A., Liggett S.B., et al. Transgenic G alpha q overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8121-8126
35. Milano C.A., Dolber P.C., Rockman H.A., Bond R.A., Venable M.E., Allen L.F., et al. Myocardial expression of a constitutively active α1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 91:1994;10109-10113
36. Vecchione C., Fratta L., Rizzoni D., Notte A., Poulet R., Porteri E., et al. Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation. 105:2002;1700-1707
37. Lemire I., Ducharme A., Tardif J.C., Poulin F., Jones L.R., Allen B.G., et al. Cardiac-directed overexpression of wild-type alpha 1B-adrenoreceptor induces dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 281:2001;931-938
38. Sakata Y., Hoit B.D., Liggett S.B., Walsh R.A., Dorn G.W. II Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation. 97(15):1998;1488-1495
39. Esposito G., Rapacciuolo A., Naga Prasad S.V., Takaoka H., Thomas S.A., Koch W.J., et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 105(1):2002;85-92
40. Adams J.W., Brown J.H. G-proteins in growth and apoptosis: lessons from the heart. Oncogene. 20(13):2001;1626-1634
41. Sabri A., Wilson B.A., Steinberg S.F. Dual actions of the Galpha(q) agonist Pasteurella multocida toxin to promote cardiomyocyte hypertrophy and enhance apoptosis susceptibility. Circ. Res. 90(8):2002;850-857
42. Dorn G.W. II Adrenergic pathways and left ventricular remodeling. J. Card. Fail. 8:2002;370-373
43. Iwase M., Bishop S.P., Uechi M., Vatner D.E., Shannon R.P., Kudej R.K., et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ. Res. 78(4):1996;517-524
44. Gaudin C., Ishikawa Y., Wight D.C. Overexpression of Gs alpha protein in the hearts of transgenic mice. J. Clin. Invest. 95(4):1995;1676-1683
45. Antos C.L., Frey N., Marx S.O., Reiken S., Gaburjakova M., Richardson J.A., et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ. Res. 89(11):2001;997-1004
46. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al. Effect of oral milrinone on mortality in severe chronic heart failure.The PROMISE Study Research Group. N. Engl. J. Med. 325(21):1991;1468-1475
47. Kouchi I., Zolk O., Jockenhovel F., Itter G., Linz W., Cremers B., et al. Increase in G(i alpha) protein accompanies progression of post-infarction remodeling in hypertensive cardiomyopathy. Hypertension. 36(1):2000;42-47
48. Zou Y., Komuro I., Yamazaki T., Kudoh S., Uozumi H., Kadowaki T., et al. Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J. Biol. Chem. 274(14):1999;9760-9770
49. Bohm M., Kirchmayr R., Erdmann E. Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock. Cardiovasc. Res. 30(4):1995;611-618
50. Eschenhagen T., Mende U., Nose M., Schmitz W., Scholz H., Haverich A., et al. Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure. Circ. Res. 70(4):1992;688-696
51. Asai K., Yang G.P., Geng Y.J., Takagi G., Bishop S., Ishikawa Y., et al. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. J. Clin. Invest. 104(5):1999;551-558
52. Nishizuka Y. Studies and perspectives of protein kinase C. Science. 1986;305-312
53. Braz J.c, Gregory K., Pathak A., Zhao W., Sahin B., Klevitsky R., et al. PKC-α regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10:2004;248-254
54. Garrington T.P., Johnson G.L. Organization and regulation of mitogen-activated protein kinase signalling pathways. Curr. Opin. Cell. Biol. 11:1999;211-218
55. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19:2000;6341-6350
56. Nicol R.L., Frey N., Pearson G., Cobb M., Richardson J., Olson E.N. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 20:2001;2757-2767
57. Minamino T., Yujiri T., Terada N., Taffet G.E., Michael L.H., Johnson G.L., et al. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc. Natl. Acad. Sci. U.S.A. 99:2002;3866-3871
58. Sadoshima J., Montagne O., Wang Q., Yang G., Warden J., Liu J., et al. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J. Clin. Invest. 110:2002;271-279
59. Sugden P.H., Clerk A. 'Stress-responsive' mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen activated protein kinases) in the myocardium. Circ. Res. 24:1998;345-352
60. Clerk A., Michael A., Sudgen P.H. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J. Cell Biol. 142:1998;523-535
61. Zhang D., Gaussin V., Taffet G.E., Belaguli N.S., Yamada M., Schwartz R.J., et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6:2000;556-563
62. Behr T.M., Nerurkar S.S., Nelson A.H., Coatney R.W., Woods T.N., Sulpizio A., et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation. 104(11):2001;1292-1298
63. Matsui T., Nagoshi T., Rosenzweig A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle. 2(3):2003;220-223
64. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296(5573):2002;1655-1657. [Review]
65. Condorelli G., Drusco A., Stassi G., Bellacosa A., Roncarati R., Iaccarino G., et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99(19):2002;12333- 12338
66. Shioi T., Kang P.M., Douglas P.S., Hampe J., Yballe C.M., Lawitts J., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19(11):2000;2537-2548
67. Matsui T., Li L., Wu J.C., Nagoshi T., Picard M.H., Liao R., et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277:2002;22896-22901
68. Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Sun H., Sasaki T., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 110(6):2002;737-749
69. Clerk A., Cole S.M., Cullingford T.E., Harrison J.G., Jormakka M., Valks D.M. Regulation of cardiac myocyte cell death. Pharmacol. Ther. 97(3):2003;223-261. [Review]
70. Tran H., Brunet A., Griffith E.C., Greenberg M.E. The many forks in FOXO's road. Sci. STKE. 2003(172):2003;RE5. [Review]
71. Brunet A., Datta S.R., Greenberg M.E. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 11(3):2001;297-305. [Review]
72. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 275(15):2000;10761-10766
73. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U.S.A. 98(20):2001;11598-11603
74. McMullen J.R., Shioi T., Zhang L., Tarnavski O., Sherwood M.C., Kang P.M., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 100(21):2003 (Oct 14);12355-12360
75. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359(Pt 1):2001;1-16. [Review]
76. Zhou P., Sun L.J., Dotsch V., Wagner G., Verdine G.L. Solution structure of the core NFATC1/DNA complex. Cell. 92(5):1998;687-696
77. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151(1):2000;117-130
78. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378(6559):1995;785-789
79. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U.S.A. 99(2):2002;907-912
80. Badorff C., Ruetten H., Mueller S., Stahmer M., Gehring D., Jung F., et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J. Clin. Invest. 109(3):2002 (Feb);373-381
81. Brancaccio M., Guazzone S., Menini N., Sibona E., Hirsch E., De Andrea M., et al. l. Melusin is a new muscle-specific interactor for beta(1) integrin cytoplasmic domain. J. Biol. Chem. 274(41):1999 (Oct 8);29282-29288
82. Brancaccio M., Fratta L., Notte A., Hirsch E., Poulet R., Guazzone S., et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat. Med. 9(1):2003 (Jan);68-75
83. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15:1997;797-819. [Review]
84. Hirano T. Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. 16(3-4):1998;249-284. Review
85. Uozumi H., Hiroi Y., Zou Y., Takimoto E., Toko H., Niu P., et al. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J. Biol. Chem. 276(25):2001;23115-23119
86. Hirota H., Chen J., Betz U.A., Rajewsky K., Gu Y., Ross J. J.R., et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 97(2):1999;189-198
87. Matsubara L.S., Matsubara B.B., Okoshi M.P., Cicogna A.C., Janicki J.S. Alterations in myocardial collagen content affect rat papillary muscle function. Am. J. Physiol. Heart Circ. Physiol. 279(4):2000 (Oct);H1534
88. Jalil J.E., Doering C.W., Janicki J.S., Pick R., Clark W.A., Abrahams C., et al. Structural vs. contractile protein remodeling and myocardial stiffness in hypertrophied rat left ventricle. J. Mol. Cell Cardiol. 20(12):1988;1179-1187
89. Jalil J.E., Doering C.W., Janicki J.S., Pick R., Shroff S.G., Weber K.T. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res. 64(6):1989;1041-1050
90. Manabe I., Shindo T., Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ. Res. 91(12):2002;1103-1113. [Review]
91. Li Y., Kishimoto I., Saito Y., Harada M., Kuwahara K., Izumi T., et al. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation. 106(13):2002;1722-1728
92. MacLennan D.H., Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Reviews. 4:2003;566-577
93. Minamisawa S., Hoshijima M., Chu G., Ward C.A., Frank K., Gu Y., et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 99:1999;313-322
94. Engelhardt S., Hein L., Dyachenkow V., Kranias E.G., Isenberg G., Lohse M.J. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation. 109(9):2004;1154-1160
95. Sato Y., Kiriazis H., Yatani A., Schmidt A.G., Hahn H., Ferguson D.G., et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J. Biol. Chem. 276:2001;9392-9399
96. Freeman K., Lerman I., Kranias E.G., Bohlmeyer T., Bristow M.R., Lefkowitz R.J., et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J. Clin. Invest. 107:2001;967-974